| [1] |
Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2):74-108. doi: 10.3322/canjclin.55.2.74
|
| [2] |
世界卫生组织.癌症实况报道(第297号)[EB/OL]. [2014-02-01]. http://www.who.int/mediacentre/factsheets/fs297/zh/index.html.
World Health Organization. Live report of cancer(No.297) [EB/OL]. [2014-02-01]. http://www.who.int/mediacentre/factsheets/fs297/zh/index.html.
|
| [3] |
Kim HR, Cheon SH, Rha SY, et al. Treatment of recurrent hepatocellular carcinoma after liver transplantation[J]. Asia Pac J Clin Oncol, 2011, 7(3):258-269. doi: 10.1111/ajco.2011.7.issue-3
|
| [4] |
Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis[J]. Liver Transpl, 2004, 10(4):534-540. doi: 10.1002/(ISSN)1527-6473
|
| [5] |
Couzin-Frankel J. Immune therapy steps up the attack[J]. Science, 2010, 330(6003):440-443. doi: 10.1126/science.330.6003.440
|
| [6] |
No authors listed. Breakthrough of the year. areas to watch[J]. Science, 2012, 338(6114):1528-1529. doi: 10.1126/science.338.6114.1528
|
| [7] |
Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age[J]. Nature, 2011, 480(7378):480-489. doi: 10.1038/nature10673
|
| [8] |
Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age[J]. J Clin Oncol, 2011, 29(36):4828-4836. doi: 10.1200/JCO.2011.38.0899
|
| [9] |
Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy[J]. Science, 2013, 342(6165):1432-1433. doi: 10.1126/science.342.6165.1432
|
| [10] |
Lizée G, Overwijk WW, Radvanyi L, et al. Harnessing the power of the immune system to target cancer[J]. Annu Rev Med, 2013, 64:71-90. doi: 10.1146/annurev-med-112311-083918
|
| [11] |
Vivarelli M, Cucchetti A, Piscaglia F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression[J]. Liver Transpl, 2005, 11(5):497-503. doi: 10.1002/(ISSN)1527-6473
|
| [12] |
Takada Y, Kaido T, Asonuma K, et al. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation[J]. Liver Transpl, 2013, 19(8):896-906. doi: 10.1002/lt.23679
|
| [13] |
Vivarelli M, Cucchetti A, La Barba G, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence[J]. Ann Surg, 2008, 248(5):857-862. doi: 10.1097/SLA.0b013e3181896278
|
| [14] |
Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma[J]. J Hepatol, 2013, 59(6):1193-1199. doi: 10.1016/j.jhep.2013.07.012
|
| [15] |
Toso C, Merani S, Bigam DL, et al. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma[J]. Hepatology, 2010, 51(4):1237-1243. doi: 10.1002/hep.23437
|
| [16] |
Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2013, 37(4):411-419. doi: 10.1111/apt.12185
|
| [17] |
Schnitzbauer AA, Zuelke C, Graeb C, et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma[J]. BMC Cancer, 2010, 10:190. doi: 10.1186/1471-2407-10-190
|
| [18] |
Alegre C, Jiménez C, Manrique A, et al. Everolimus monotherapy or combined therapy in liver transplantation: indications and results[J]. Transplant Proc, 2013, 45(5):1971-1974. doi: 10.1016/j.transproceed.2013.01.075
|
| [19] |
Maggs JR, Suddle AR, Aluvihare V, et al. Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2012, 35(10):1113-1134. doi: 10.1111/apt.2012.35.issue-10
|
| [20] |
安玉玲, 张婷婷, 蔡常洁, 等.西罗莫司用于治疗肝癌肝移植术后肿瘤复发患者的疗效分析[J].器官移植, 2011, 2(2):73-76. http://www.organtranspl.com/browse/detail/qkid/51/id/475.html
An YL, Zhang TT, Cai CJ, et al. Effect of sirolimus application on liver allograft recipients with tumor recurrence[J]. Organ Transplant, 2011, 2(2):73-76. http://www.organtranspl.com/browse/detail/qkid/51/id/475.html
|
| [21] |
Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial[J]. Lancet, 2000, 356(9232):802-807. doi: 10.1016/S0140-6736(00)02654-4
|
| [22] |
Cui J, Wang N, Zhao H, et al. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma[J]. Int J Cancer, 2014, 134(2):342-351. doi: 10.1002/ijc.28372
|
| [23] |
Huang ZM, Li W, Li S, et al. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients[J]. J Immunother, 2013, 36(5):287-293. doi: 10.1097/CJI.0b013e3182948452
|
| [24] |
Ma Y, Xu YC, Tang L, et al. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety[J]. Exp Hematol Oncol, 2012, 1(1):11. doi: 10.1186/2162-3619-1-11
|
| [25] |
Palmer DH, Midgley RS, Mirza N, et al. A phase Ⅱ study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma[J]. Hepatology, 2009, 49(1):124-132. doi: 10.1002/hep.22626
|
| [26] |
El Ansary M, Mogawer S, Elhamid SA, et al. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC[J]. J Cancer Res Clin Oncol, 2013, 139(1):39-48. doi: 10.1007/s00432-012-1298-8
|
| [27] |
Tada F, Abe M, Hirooka M, et al. Phase Ⅰ/Ⅱ study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma[J]. Int J Oncol, 2012, 41(5):1601-1609. http://cn.bing.com/academic/profile?id=2122222213&encoded=0&v=paper_preview&mkt=zh-cn
|
| [28] |
Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants[J]. Science, 2002, 295(5562):2097-2100. doi: 10.1126/science.1068440
|
| [29] |
Ohira M, Ishiyama K, Tanaka Y, et al. Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice[J]. J Clin Invest, 2009, 119(11):3226-3235. http://cn.bing.com/academic/profile?id=2114547650&encoded=0&v=paper_preview&mkt=zh-cn
|
| [30] |
Introna M, Franceschetti M, Ciocca A, et al. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation[J]. Bone Marrow Transplant, 2006, 38(9):621-627. doi: 10.1038/sj.bmt.1705503
|
| [31] |
Laport GG, Sheehan K, Baker J, et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant, 2011, 17(11):1679-1687. doi: 10.1016/j.bbmt.2011.05.012
|
| [32] |
Linn YC, Niam M, Chu S, et al. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies[J]. Bone Marrow Transplant, 2012, 47(7):957-966. doi: 10.1038/bmt.2011.202
|
| [33] |
Mehta BA, Schmidt-Wolf IG, Weissman IL, et al. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells[J]. Blood, 1995, 86(9):3493-3499. http://cn.bing.com/academic/profile?id=88796997&encoded=0&v=paper_preview&mkt=zh-cn
|
| [34] |
Brewin J, Mancao C, Straathof K, et al. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease[J]. Blood, 2009, 114(23):4792-4803. doi: 10.1182/blood-2009-07-228387
|
| [35] |
Eissens DN, Van Der Meer A, Van Cranenbroek B, et al. Rapamycin and MPA, but not CsA, impair human NK cell cytotoxicity due to differential effects on NK cell phenotype[J]. Am J Transplant, 2010, 10(9):1981-1990. doi: 10.1111/j.1600-6143.2010.03242.x
|
| [36] |
Nishida S, Levi DM, Tzakis AG. Liver natural killer cell inoculum for liver transplantation with hepatocellular carcinoma[J]. Curr Opin Organ Transplant, 2013, 18(6):690-694. http://cn.bing.com/academic/profile?id=2003917966&encoded=0&v=paper_preview&mkt=zh-cn
|
| [37] |
Kayashima H, Toshima T, Okano S, et al. Intratumoral neoadjuvant immunotherapy using IL-12 and dendritic cells is an effective strategy to control recurrence of murine hepatocellular carcinoma in immunosuppressed mice[J]. J Immunol, 2010, 185(1):698-708. doi: 10.4049/jimmunol.0900187
|
| [38] |
Ohira M, Nishida S, Tryphonopoulos P, et al. Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma[J]. Cell Transplant, 2012, 21(7):1397-1406. doi: 10.3727/096368911X627589
|
WeChat Subscription Account
Wechat Service Account
Supported by:
Beijing Renhe Information Technology Co. Ltd
DownLoad: